Please login to the form below

Not currently logged in
Email:
Password:

Astellas files combination urology product EC905 in Europe

Netherlands filing to treat symptoms of benign prostatic hyperplasia paves way for rest of Europe

Astellas Pharma has filed for approval of a new drug to treat the symptoms of benign prostatic hyperplasia (BPH) in the Netherlands, starting the process for EU-wide registration.

The new product, called EC905, is a fixed-dose combination of solifenacin and tamsulosin and has been filed with a proposed indication of treating lower urinary tract symptoms (LUTS) associated with BPH.

EC905 combines the active ingredients of two of Astellas' top-selling products, namely Harnal (tamsulosin) and Vesicare (solifenacin succinate).

To date BPH patients have often had to take a combination of different products to manage their symptoms effectively, and EC905 aims to reduce pill burden and maintain efficacy and tolerability.

The Dutch filing is based on the results of the phase III NEPTUNE study, which were presented at the end of February at the European Association of Urology congress in Paris.

In that study, EC905 improved LUTS in men aged over 45 with both voiding and storage symptoms, performing better than both placebo and tamsulosin monotherapy.

LUTS are common in men and include symptoms of voiding, including hesitancy and intermittency, as well as storage symptoms (frequency, urgency, nocturia) and feelings of incomplete bladder emptying.

In a study of four European countries plus Canada, LUTS was found to affect more than 60 per cent of the adult male population.

Astellas has made urology one of its main therapeutic franchises, and has previously said it aims to achieve sales of 170bn yen ($2bn) in this category in fiscal 2014.

EC905 is one of the foundations of that strategy in Europe, extending Astellas' Harnal and Vesicare monotherapy products, which achieved sales of 66.5bn yen ($800m) and 86.7bn yen ($1bn), respectively, in fiscal 2010.

28th March 2012

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

Lifting the fog to help Clinical Labs navigate IVDR 2022
In Vitro Diagnostic Regulation (IVDR 2022) was on the horizon: a new regulatory basis for laboratories to adhere to regarding their diagnostic equipment and tests. BD wanted to let their...
Empowering adolescents to manage emotional and mental health issues
1 in 10 UK children suffer with a mental health issue and alarmingly as many as 70% of these don’t receive the proper support they need. That’s why The Anna...
Reframing rare to increase earlier diagnosis of Gaucher Disease
Sanofi Genzyme wanted to reach haematologists; the specialist physicians most likely to encounter patients with Gaucher Disease prior to diagnosis. The problem? Gaucher Disease is considered very rare and its...